Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 9;9:730240. doi: 10.3389/fcell.2021.730240

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Lu, Jin, Du, Hu, Wei, Wang, Li and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Genomic alterations of ICB and lenvatinib target genes. (A) The most common types of cancers with particularly ICB and lenvatinib target genes alterations. (B) The most common types of target alterations in each cancer type. (C) Driver alterations types and proportions of ICB and lenvatinib target genes in different cancer types. The color of the block represents the proportion of alterations, and the number represents the percentage of alterations. Above is a column chart of alteration types in different cancer types, and on the left is a column chart of alteration types in different targets. ACC, adrenocortical carcinoma; DBLC, diffuse large B-cell lymphoma; LGG, low grade glioma; LAML, acute myeloid leukemia; MESO, mesothelioma; TGCT, testicular germ cell tumors; UCS, uterine carcinosarcoma; UVM, uveal melanoma.